COMP <GO>
TAK vs TEVA // EV/EBITDA & P/E VALUATION
Takeda Pharmaceutical Company Limited American (NYSE) VS. Teva Pharmaceutical Industries Limited (NYSE) • 15-METRIC TALLY: TAK 8
— TEVA 4
▲ EV/EBITDA & P/E VALUATION LEADER: TEVA
LAST: $20.91 (+4.50%) • MKT CAP: $63.23B
valuation
21.0x
LAST: $42.09 (+1.50%) • MKT CAP: $48.32B
valuation
20.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TAK VS. TEVA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TAK | TEVA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 51.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 9.40% | +0.50 | TAK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.0x | 20.8x | +0.20 | TEVA | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 1.81% | +0.40 | TAK | /fcf-yield <GO> |
| Operating Margin | 13.90% | 12.50% | +1.40 | TAK | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 8.20% | +2.70 | TAK | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 4.30% | -7.60 | TEVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 1.02 | +2.72 | TAK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TEVA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 58.6 | -2.00 | TEVA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.00 | +0.06 | TAK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 31.9x | -1.40 | TAK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $63.23B | $48.32B | $14.90B | TAK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TAK REV | TEVA REV | TAK GROSS % | TEVA GROSS % | TAK FCF | TEVA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $17.26B | — | 51.8% | — | $872.4M |
| FY 2024 | — | $16.54B | — | 48.7% | — | $502.5M |
| FY 2023 | — | $15.85B | — | — | — | $654.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TAK // BETA 1.06
TEVA // BETA 1.00